← Leaderboards
Ann M Ginsberg
Global Alliance For Tb Drug Development
$1,514,725
Attributed
$1,619,725
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $680K · FY2010–18$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
FDA$1,025,243 · 1
NIH$594,482 · 2
By mechanism
U18$1,025,243 · 1
U01$582,482 · 1
R13$12,000 · 1
Top collaborators
- Mark Hatherill1 shared
Others in their field
Top investigators on “Adolescent”
- Lawrence Corey · Fred Hutchinson Cancer Center$481,946,630
- Gregory H Reaman · National Childhood Cancer Foundation$264,737,004
- Barbara Driver · Westat, Inc.$232,205,725
- George R Seage · Abt Associates, Inc.$222,555,872
- Sharon A Nachman · Johns Hopkins University$213,337,729
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$198,115,770
Research focus
AdolescentAdolescent And Young AdultAdultAge GroupAmericanAnimal ModelAntibody ResponseAntigensAttenuatedAttenuated Live Virus VaccineBaseBcg VaccineBiodistributionBirthCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCell WallCessation Of LifeChildChildhoodClinical DevelopmentCollaborationsCollectionActive Control
Grant awards (5)
MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa$372,482
U01 · FY2018 · AI · contact PI
5th Global Forum on TB Vaccines$12,000
R13 · FY2018 · AI · contact PI
MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled, Safety, Immunogenicity, and Dose-escalation Study in Adults with and without Latent Tuberculosis Infection in South Africa$210,000
U01 · FY2017 · AI · contact PI
Consortium for TB Biomarkers$345,243
U18 · FY2011 · FD · contact PI
Consortium for TB Biomarkers$680,000
U18 · FY2010 · FD · contact PI